... little imagining that shortly after IDWeek, this site would be embroiled in various controversies -- about which many others have already weighed in wisely!
2/x
But here's a condensed version of the talk, which explains why I'm sticking around (at least for now).
Let’s start with the (dreaded) “Learning Objectives”, which I’ve tried to enliven with pic of my pup. 3/x
Here’s what changed -- three things in particular.
7/x
So why use Twitter? Am sure there are other reasons, but here are mine.
8/x
Those on other social media platforms (notably FB and instagram) might wonder how this differs.
Note that people are vastly more likely to use Twitter for professional reasons. (I got this slide from either @CarlosdelRio7 or @GermHunterMD, thank you for sharing!) 9/x
If you're reading this for the first time, and don't have an account, here’s how to get started. 10/x
My profile, plus one of my co-presenter’s at this IDWeek session.
11/x
Can't resist sharing @jrarribas' profile, which makes me laugh every time I see it! 😂
(By the way, he assures me all the acronyms are real. Es verdad!) 12/x
Now, onto the structure of an IDTweet, using a splendid example from @richdavisphd. 13/x
Certainly you might still have questions or concerns. I address some of them here.
Note I prefer not to have the app on my phone (too distracting), but ymmv.
... and #5, by the way, is a joke. 14/x
Read or publish something of interest, and want to share it?
Here's a paper published in @CIDJournal by @DrJRMarcelin et al with an important equity message. 15/x
Keeping up with the literature is greatly facilitated by this site, especially with smart and prolific posters such as @ABsteward.
FYI, had never even *heard* of cefepime/enmetazobactam before this post. Hey -- you can learn a lot here! 16/x
Sometimes authors of important studies start a dialogue with readers, answering their queries.
So much better (and faster) than traditional “Letters to the Editor” in journals, which can take weeks or even months to come out. 17/x
One of the most useful teaching strategies is to put together an educational Twitter thread of linked posts, or “tweetorial” -- and @tony_breu is a master.
For me, keeping up with the latest science on Covid19 would not have been possible without smart and generous scientists sharing their expertise, such as @DrJLi and @EricTopol, among *many* others.
The field simply moves too fast.
So if you've figured out a good way to teach a complex subject, sharing it via a Tweetorial is just the thing!
Here @Darcy_ID_doc offers this stellar review of HIV resistance testing.
Ever submit a paper to a high-quality, high-impact factor journal and have it rejected, even though the reviews are mostly good and eminently addressable?
Certainly I have. 🙋♂️
1/x
Wouldn't it be awesome if those reviews could be used by another journal?
Peer review, after all, is a limited but critical resource in academic medicine.
Why should these reviews go to waste? And getting good peer review takes time!
2/x
That's why I'm delighted to announce that @CIDJournal -- and soon *all* the @IDSA journals -- will accept outside reviews from other high-impact journals. Some details in screen captures below. 3/x academic.oup.com/cid/pages/Manu…
Since talks on Covid get out of date as soon as you click "save", might as well post the talk given this week at @harvardmed Medical Grand Rounds, along with by @k_stephensonMD@SanjatKanjilal and Dr. Ruanne Barnabas
Here's the topic: 1/x
Let’s start with the controversy over disease severity, subject that appears both to excite and annoy people (for reasons that I hope to explain)
Also, a reminder that Omicron was a (very unwelcome) 2022 holiday "gift" -- will always link it to Thanksgiving!
2/X
These early anecdotal reports came from South Africa that the disease was milder with Omicron.
True? Or just wishful thinking? 3/X
We HIV/ID clinicians have been dealing with these for years.
Yes it's a long list, but five days will seem relatively manageable compared with chronic ritonavir administration, especially since the effect is quick on/quick off.
Some drugs on this list (e.g. statins) can be held for 5 days. Others (calcineurin inhibitors) dose-reduced and monitored. Some aren't used very often any more. There are alternatives that can be temporarily substituted in some pts (e.g. lorazepam for clonazepam).
3/x
Yesterday I posted a long thread on the extraordinary progress we’ve made in HIV care and research since report of the first cases 40 years ago. Now for Part 2!
(I stopped at around year 20. Here’s the link to Part 1, in case you want to catch up
When we left off, we'd experienced the thrill of effective combination ART. Our 2 major news magazines featured advances in HIV on their covers! One of these guys was a basketball star, the other an HIV researcher -- see if you can guess which one is which
2/x
But the excitement of having effective ART was tempered by the realization that these treatments had major issues, including side effects, high pill burdens, and low resistance barriers. The "when to start?" question became a central part of HIV care
The "History of HIV" talk I gave last week actually has this title, which I don't think is an overstatement. Posting it now with gratitude, just in time for Thanksgiving (my favorite holiday -- the gratitude and family part).
(Part 1 thread) 1/x
Must start with this 1981 @CDCMMWR report of 5 cases of PCP in Los Angeles. Have already commented on the surprising page 2 placement. There's a story behind it, right @deborahcottonmd? (Later moved to Page 1 on reprints.) Note “blue diazo” slide style
2/x
During my first year of med school, we had one lecture on AIDS, with putative causes. Not an auspicious start.
(Yes, 1983. I'm old.)